University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Benjamin Kim, M.D.

Blood disorder specialist

Dr. Benjamin Kim is a hematologist who treats patients with non-malignant blood diseases such as hemophilia, von Willebrand's disease, platelet function disorders, deep vein thrombosis (DVT)/pulmonary embolism (PE), anemia and thrombocytopenia. His research interests include analyzing large patient datasets and assessing the cost-effectiveness of personalized therapies to improve outcomes, particularly for bleeding and clotting disorders. In addition, he aims to improve the transition from pediatric to adult care for adolescents and young adults with hemophilia.

A native of Chicago, Kim completed his undergraduate degree, medical school and residency training in internal medicine at Northwestern University. He then completed his fellowship training in hematology and oncology at UCLA, where he was the chief fellow, and doctoral studies in policy analysis at the Pardee RAND Graduate School. His professional activities include serving as an executive board member of the Hemostasis & Thrombosis Research Society, a fellow of the Haemophilia Academy and an adjunct researcher at the RAND Corporation. He is board-certified in hematology and medical oncology.


Hematology and Blood and Marrow Transplant
400 Parnassus Ave.,
Suite A-502
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051

Hours: Monday to Friday
8 a.m. – 5 p.m

Hemophilia Treatment Center
400 Parnassus Ave., Fifth Floor, Suite A-502
San Francisco, CA 94143
Phone: (415) 353-2421
Fax: (415) 353-2467

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Benjamin Kim

Additional Languages



Northwestern University Feinberg School of Medicine 2003
Pardee RAND Graduate School, Policy Analysis 2011


Northwestern Memorial Hospital, Internal Medicine 2006


Ronald Reagan UCLA Medical Center, Hematology-Oncology 2011

Selected Research and Publications

  1. Ryoo JJ, Malin JL, Ordin DL, Oishi SM, Kim B, Asch SM, He R, Gould MK. Facility characteristics and quality of lung cancer care in an integrated health care system. J Thorac Oncol. 2014 Apr; 9(4):447-55.
  2. Kim B, Hing ZA, Wu A, Schiller T, Struble EB, Liuwantara D, Kempert PH, Broxham EJ, Edwards NC, Marder VJ, Simhadri VL, Sauna ZE, Howard TE, Kimchi-Sarfaty C. Single-nucleotide variations defining previously unreported ADAMTS13 haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family. Br J Haematol. 2014 Apr; 165(1):154-8.
  3. Houchens N, Dhaliwal G, Askari F, Kim B, Saint S. Clinical problem-solving. The essential element. N Engl J Med. 2013 Apr 4; 368(14):1345-51.
  4. Kim B, Schroeder BE, Schnabel CA, Erlander MG, Malin JL. Physician-reported clinical utility of the 92-gene molecular classifier in tumors with uncertain diagnosis following standard clinicopathologic evaluation. Pers Med Oncol. 2013; 2(2):68-76.
  5. Jacquot C, Moayeri M, Kim B, Shugarts S, Lynch KL, Leavitt AD. Prolonged ceftriaxone-induced immune thrombocytopenia due to impaired drug clearance: a case report. Transfusion. 2013 Nov; 53(11):2715-21.
  6. Sauna ZE, Ameri A, Kim B, Yanover C, Viel KR, Rajalingam R, Cole SA, Howard TE. Observations regarding the immunogenicity of BDD-rFVIII derived from a mechanistic personalized medicine perspective. J Thromb Haemost. 2012 Sep; 10(9):1961-5.
  7. Young P, Kim B, Malin JL. Preoperative breast MRI in early-stage breast cancer. Breast Cancer Res Treat. 2012 Oct; 135(3):907-12.
  8. Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum U. Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract. 2012 May; 8(3 Suppl):e24s-30s.
  9. Potosky AL, Malin JL, Kim B, Chrischilles EA, Weeks JC. Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst. 2011 Dec 21; 103(24):1899-901; author reply 1901-3.
  10. Kim B, Roth C, Young VL, Chung KC, van Busum K, Schnyer C, Mattke S. Anaplastic large cell lymphoma and breast implants: results from a structured expert consultation process. Plast Reconstr Surg. 2011 Sep; 128(3):629-39.
  11. Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, Weeks JC. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst. 2011 Jun 22; 103(12):979-82.
  12. Kim B, Roth C, Chung KC, Young VL, van Busum K, Schnyer C, Mattke S. Anaplastic large cell lymphoma and breast implants: a systematic review. Plast Reconstr Surg. 2011 Jun; 127(6):2141-50.
  13. Oratz R, Kim B, Chao C, Skrzypczak S, Ory C, Bugarini R, Broder M. Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract. 2011 Mar; 7(2):94-9.
  14. Scheuner MT, de Vries H, Kim B, Meili RC, Olmstead SH, Teleki S. Are electronic health records ready for genomic medicine? Genet Med. 2009 Jul; 11(7):510-7.
  15. Bennett CL, Kim B, Zakarija A, Bandarenko N, Pandey DK, Buffie CG, McKoy JM, Tevar AD, Cursio JF, Yarnold PR, Kwaan HC, De Masi D, Sarode R, Raife TJ, Kiss JE, Raisch DW, Davidson C, Sadler JE, Ortel TL, Zheng XL, Kato S, Matsumoto M, Uemura M, Fujimura Y. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007 Sep 18; 50(12):1138-43.
  16. Swisher KK, Doan JT, Vesely SK, Kwaan HC, Kim B, Lämmle B, Kremer Hovinga JA, George JN. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica. 2007 Jul; 92(7):936-43.
  17. Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005 Nov 15; 106(10):3343-7.
  18. Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005 Jul 1; 106(1):241-6.
  19. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004 Sep 30; 351(14):1403-8.
  20. Zakarija A, Bandarenko N, Pandey DK, Auerbach A, Raisch DW, Kim B, Kwaan HC, McKoy JM, Schmitt BP, Davidson CJ, Yarnold PR, Gorelick PB, Bennett CL. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke. 2004 Feb; 35(2):533-7.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.